BVT Aktienanleihe AMD 28.06.2024/ DE000VU8J590 /
| 13/05/2024 20:03:23 | Chg.-0.010 | Bid21:55:32 | Ask21:55:32 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 101.260EUR | -0.01% | 101.240 Bid Size: 500,000 |
101.340 Ask Size: 500,000 |
Advanced Micro Devic... | 120.00 USD | 28/06/2024 | Call |
GlobeNewswire
14:50
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
14:00
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GlobeNewswire
11:00
AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire
09/05
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire
08/05
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire
08/05
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
08/05
AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire
08/05
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire
08/05
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire
07/05
Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire
07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
06/05
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire
06/05
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire
06/05
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire
06/05
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire
03/05
YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...
